CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DBRCA1ExpressionPredictiveSupportsSensitivity/ResponseMalignant MesotheliomaVinorelbineBusacca et al., 2012
CKRASG12DPredictiveSupportsSensitivity/ResponsePancreatic CarcinomaAkt Inhibitor MK2206Yap et al., 2011
CPTENLossPredictiveSupportsSensitivity/ResponsePancreatic CarcinomaAkt Inhibitor MK2206Yap et al., 2011
DHSPB1EXPRESSIONPredictiveSupportsSensitivity/ResponsePancreatic Ductal AdenocarcinomaGemcitabineSchäfer et al., 2012
DNQO1EXPRESSIONPredictiveSupportsResistanceLung CancerAmrubicinTakakuwa et al., 2011
DNQO1P187SPredictiveSupportsSensitivity/ResponseLung CancerAmrubicinTakakuwa et al., 2011
DKRASMutationPredictiveSupportsSensitivity/ResponseColorectal CancerImmunomodulatory Oligonucleotide,Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorRosa et al., 2011
DABCB1OverexpressionPredictiveSupportsResistanceLung Non-small Cell CarcinomaPaclitaxelMeng et al., 2011
BCXCR4EXPRESSIONPredictiveSupportsResistanceGastric AdenocarcinomaDocetaxelXie et al., 2010
DMAGEH1EXPRESSIONPredictiveSupportsResistanceBile Duct AdenocarcinomaGemcitabineOjima et al., 2010
DASNSAmplificationPredictiveSupportsResistanceOvarian CancerAsparaginaseLorenzi et al., 2006
DPOU5F1EXPRESSIONPredictiveSupportsResistanceColon CancerOxaliplatinWen et al., 2015
DERBB2AmplificationPredictiveSupportsSensitivity/ResponsePancreatic AdenocarcinomaAfatinibHuguet et al., 2016
DEGFRT790MPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaOsimertinib,RociletinibHirano et al., 2015
DEGFRL858RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAfatinibHirano et al., 2015
DEGFRExon 19 DeletionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAfatinibHirano et al., 2015
BFGFR1ExpressionPrognosticSupportsPoor OutcomeHead And Neck Squamous Cell CarcinomaHase et al., 2006
BCD274ExpressionPrognosticSupportsPoor OutcomeLung Non-small Cell CarcinomaTokito et al., 2016
BEGFRAmplificationPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaGefitinib,ErlotinibFiala et al., 2016
DTPM3::NTRK1FusionPredictiveSupportsSensitivity/ResponseColorectal CancerLarotrectinib,LestaurtinibPark et al., 2016
BTERTRS2736100PredisposingSupportsPredispositionBrain GliomaYuan et al., 2016
BSTAG2UnderexpressionPrognosticSupportsBetter OutcomeBladder CarcinomaQiao et al., 2016
DKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSelumetinib,B-Raf/VEGFR-2 Inhibitor RAF265Lamba et al., 2014
DKRASMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaTrametinib,AfatinibSun et al., 2014
BBRAFV600EPredictiveDoes Not SupportResistanceMelanomaMEK Inhibitor RO4987655Zimmer et al., 2014
BBRAFWildtypePredictiveDoes Not SupportResistanceMelanomaMEK Inhibitor RO4987655Zimmer et al., 2014
CNRASMutationPredictiveDoes Not SupportResistanceMelanomaMEK Inhibitor RO4987655Zimmer et al., 2014
BKRASMutationPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerMEK Inhibitor RO4987655Zimmer et al., 2014
CBRAFV600PredictiveSupportsResistanceMelanomaRefametinibWeekes et al., 2013
CKRASMutationPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerRefametinibWeekes et al., 2013
DBRAFV600EPredictiveSupportsSensitivity/ResponseMelanomaDactolisib,SelumetinibPenna et al., 2016
BMRE11FrameshiftPredictiveSupportsSensitivity/ResponseProstate CancerOlaparibMateo et al., 2015
CKITEXPRESSIONPredictiveSupportsSensitivity/ResponseEndometrial CancerImatinibKalender et al., 2009
CKITEXPRESSIONPredictiveSupportsSensitivity/ResponseEndometrial CancerImatinibSalvatierra et al., 2006
BTP53MutationPrognosticSupportsPoor OutcomeAdrenocortical CarcinomaSidhu et al., 2005
BHIF1A3' UTR PolymorphismPrognosticSupportsPoor OutcomePancreatic AdenocarcinomaWang et al., 2016
BHIF1AOVEREXPRESSIONPrognosticSupportsPoor OutcomeSarcomaShintani et al., 2006
BFLT3ITDPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaSorafenibMan et al., 2012
BERBB2AmplificationPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaTrastuzumabGatzemeier et al., 2004
BPSMB8NUCLEAR EXPRESSIONPrognosticSupportsPoor OutcomeGastric AdenocarcinomaKwon et al., 2016
BPBKNUCLEAR EXPRESSIONPrognosticSupportsPoor OutcomeGastric AdenocarcinomaKwon et al., 2016
BPTTG1OVEREXPRESSIONPrognosticSupportsPoor OutcomeMeningiomaSchmidt et al., 2016
BLEPRUNDEREXPRESSIONPrognosticSupportsPoor OutcomeMeningiomaSchmidt et al., 2016
EEREGEXPRESSIONPrognosticSupportsPoor OutcomeLung AdenocarcinomaBauer et al., 2017
BETS2RS461155PredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCisplatin,PaclitaxelHong et al., 2016
DKRT18UNDEREXPRESSIONPrognosticSupportsPoor OutcomeProstate CancerYin et al., 2016
CSS18::SSX4FusionDiagnosticSupportsPositiveSynovial SarcomaSkytting et al., 1999
CEGFRS492RPredictiveSupportsSensitivity/ResponseColorectal CancerPanitumumabMontagut et al., 2012
DEGFRR451CPredictiveSupportsSensitivity/ResponseColorectal CancerCetuximab,Panitumumab,Futuximab/Modotuximab MixtureSánchez-Martín et al., 2016
BERBB2AmplificationPredictiveDoes Not SupportSensitivity/ResponseEndometrial CancerTrastuzumabFleming et al., 2010
Page 69 of 96
PreviousNext